Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 11/20 | 0.38 |
| ▸ | SRC | P12931 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ROS1 | P08922 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24133460 | 0.79 | RIPK2 (0.39) | RIPK2SRCKDRLCKKCNH2 | |
| SCHEMBL8308145 | 0.78 | HPGD (0.49) | RIPK2SRCKDRLCKABL1 | |
| SCHEMBL8310297 | 0.78 | SRC (0.61) | RIPK2SRCKDRKCNH2PIK3CD | |
| SCHEMBL3691443 | 0.77 | KDM4E (0.50) | KDRHPGDSMN1; SMN2 | |
| SCHEMBL15613500 | 0.77 | ADORA1 (0.47) | RIPK2SRCKDRLCKABL1 | |
| SCHEMBL8357891 | 0.76 | HPGD (0.51) | RIPK2SRCABL1HPGDSMN1; SMN2 | |
| SCHEMBL8310247 | 0.74 | KIF11 (0.41) | RIPK2SRCKDRLCKABL1 | |
| SCHEMBL16263384 | 0.72 | LMNA (0.38) | RIPK2SRCKDRLCKTGFBR1 | |
| SCHEMBL8309258 | 0.72 | ADORA1 (0.48) | RIPK2PIK3CDPIK3CGHPGDSMN1; SMN2 | |
| SCHEMBL8308115 | 0.72 | ADORA2A (0.48) | RIPK2SRCABL1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956214-B2 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956214-B2 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2999696-B1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170056389-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-03-02 | — | — | US | disclosed |
| US-20170056389-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-03-02 | — | — | US | disclosed |
| US-9518026-B2 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518026-B2 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160090362-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-31 | — | — | US | disclosed |
| US-20160090362-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-31 | — | — | US | disclosed |
| WO-2014189947-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056389-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | PCK1, DCK, CILK1 | RIPK2 417/4885SRC 1759/4885KDR 4796/4885 |
| US-20160090362-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | PCK1, DCK, CILK1 | RIPK2 417/4885SRC 1759/4885KDR 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.